Loading…
← CockpitCompetitor Analysis › PROK ProKidney Corp. Class AOpen in the cockpit ↗

ProKidney Corp. Class APROKCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 14
Mkt cap
$314M
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$1.73M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-98.8 pp
WACC 14.4%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$1.04
1D-5.5%
1W-8.0%
1M-27.8%
3M-26.8%
6M-38.5%
YTD-53.6%
1Y-53.8%
ATR %11.6%
Beta1.81
52w lowhigh60.8% off high

What ProKidney does

Employees: 231

ProKidney at a glance

Size ProKidney (PROK) is a United States Health Care company (Biotechnology) with a market value of $314M, the 3036th largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.04 on 18 Nov 2026.

Performance Over six months the shares fell 38.5%, against -24.7% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue grew 4.2% over the last twelve months (peer median +7.3%); the operating margin is -24,830.3% (peer median -115.0%).

Valuation It trades at 1,625.4× enterprise value to sales against a peer median of 5.3× (2nd most expensive of 15).

Capital Return on invested capital runs 98.8 points below its cost of capital (14.4% WACC).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 70PROK 59
Six months, rebased to 100: ProKidney against the median of its 20 peers (local-currency closes).

ProKidney financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$775,000$893,000$76,000$0$0
Revenue growth—+1,075%———
Gross profit-$5.03M-$4.83M-$4.26M-$3.17M-$3.04M
EBITDA-$187M-$159M-$174M-$148M-$150M
Net income-$103M-$69.0M-$61.2M-$35.5M-$108M
Free cash flow-$168M-$135M-$156M-$124M-$78.9M
Capital expenditure$14.6M$15.2M$29.5M$34.2M$1.85M
Total debt$3.25M$4.04M$3.24M$4.41M$2.40M

Quarterly statements and history in the cockpit →

ProKidney competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%7630NAUT48946945CCCC21051873GLSIGALTLRMR358570LYEL086900CRMDCTNM476060PROK6-month return →1-month return →
Up and to the right = strong over both horizons. ProKidney is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×5,000×10,000×15,000×76304894XFORCCCC358570LYEL476060PROKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. ProKidney is the large dot.

ProKidney competitors and peer comparison

How ProKidney compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

ProKidney against its 20 peers (data as of 18 Nov 2026)
MeasurePROKPeer medianRank in peer set
1-month return-27.8%-4.7%3rd lowest of 20
6-month return-38.5%-24.7%6th lowest of 20
Distance from 52-week high-60.8%-52.1%7th lowest of 20
Revenue growth (TTM)+4.2%+7.3%6th lowest of 13
Operating margin-24,830.3%-115.0%2nd lowest of 15
EV / Sales1,625.4×5.3×2nd most expensive of 15
ROIC minus cost of capital-98.8 pp-22.1 pp3rd lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are ProKidney's closest peers?
The cockpit's peer set: IMPACT Therapeutics (7630.HK), Nautilus Biotechnolgy (NAUT), Cuorips (4894.T), AP Biosciences (6945.TWO), X4 Pharmaceuticals (XFOR), C4 Therapeutics (CCCC), Laekna (2105.HK), Viva Biotech (1873.HK).
Is ProKidney expensive compared with its peers?
On ev / sales it trades at 1,625.4× against a peer median of 5.3×, 2nd most expensive of 15 in its peer set.
How has ProKidney stock performed?
Over six months to 18 Nov 2026 the shares returned -38.5% against -24.7% for the median peer; over one year -53.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.